Bone Biologics (BBLG) Accumulated Depreciation & Amortization (2016 - 2017)

Bone Biologics has reported Accumulated Depreciation & Amortization over the past 3 years, most recently at $357.0 for Q4 2017.

  • Quarterly Accumulated Depreciation & Amortization rose 36.78% to $357.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $357.0 through Dec 2017, up 36.78% year-over-year, with the annual reading at $357.0 for FY2017, 36.78% up from the prior year.
  • Accumulated Depreciation & Amortization was $357.0 for Q4 2017 at Bone Biologics, up from $333.0 in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $3982.0 in Q4 2015 and troughed at $141.0 in Q1 2016.
  • The 3-year median for Accumulated Depreciation & Amortization is $285.0 (2017), against an average of $674.44.
  • Year-over-year, Accumulated Depreciation & Amortization plummeted 93.45% in 2016 and then surged 102.13% in 2017.
  • A 3-year view of Accumulated Depreciation & Amortization shows it stood at $3982.0 in 2015, then plummeted by 93.45% to $261.0 in 2016, then soared by 36.78% to $357.0 in 2017.
  • Per Business Quant, the three most recent readings for BBLG's Accumulated Depreciation & Amortization are $357.0 (Q4 2017), $333.0 (Q3 2017), and $309.0 (Q2 2017).